Hologic, Inc.(HOLX)
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Latest News & Analysis
Hologic's Q4 Earnings Validate PE Acquisition Thesis Amid Integration Success
Q4 earnings validate the Blackstone and TPG acquisition thesis with 6.2% organic growth and 31.2% operating margins despite integration activity.
Blackstone and TPG Acquire Hologic for $79 Per Share, Taking Women's Health Leader Private
Blackstone and TPG acquire women's health leader for $79 per share, taking the medical device specialist private and reshaping capital allocation strategy.
Hologic: Molecular Diagnostics Market Growth, FDA Clearances, and Strategic Outlook
Hologic’s latest FDA clearance, Q1 earnings results, and strategic moves underscore robust growth in the molecular diagnostics market.
Hologic: Navigating Market Trends in Women's Health Diagnostics
Hologic navigates market trends with new CE Mark, FDA clearance, and strategic expansions, amidst sales guidance adjustments. Read the full intraday analysis.
Hologic (HOLX): Navigating Growth in Molecular Diagnostics and Women's Health
Hologic (HOLX) navigates growth in molecular diagnostics and women's health with new FDA and CE Mark approvals amid macroeconomic challenges. Key insights for investors.
Hologic (HOLX): Navigating Regulatory Successes and Headwinds
Hologic navigates regulatory wins amid macroeconomic headwinds. FDA and CE Mark approvals boost diagnostics and breast health, but currency and supply chains pose challenges.
Hologic (HOLX): Analysis of Q1 2025 Results, Regulatory Wins, and Market Outlook
A comprehensive analysis of Hologic's Q1 2025 results, regulatory wins, and market outlook amid macroeconomic headwinds and competitive pressures.
Hologic Inc. (HOLX): Q1 2025 Analysis, Surgical Growth
A comprehensive analysis of Hologic Inc.'s Q1 2025 performance, strategic initiatives, and future outlook, focusing on surgical growth and regulatory milestones.
Hologic (HOLX): Developments, Market Impact, and Industry Trends
Hologic Inc. (HOLX) navigates a dynamic market with regulatory wins and macro challenges. A deep dive into its strategic outlook and key trends.
Hologic (HOLX) Stock Analysis: Earnings, Regulatory Approvals, and Market Outlook
Analysis of Hologic (HOLX) stock, focusing on earnings, regulatory approvals, and market outlook. Key insights for investors and analysts.
Hologic (HOLX): Navigating Macro Headwinds with Innovation
Hologic (HOLX) faces macro headwinds but sees growth in Surgical business and new product launches. Investor scrutiny intensifies amid stock decline.
Hologic (HOLX) Stock Analysis: Growth, R&D, and Sector Trends
Comprehensive Hologic stock analysis examining performance, growth drivers, and investor sentiment. Surgical business drives growth amidst macroeconomic concerns.
Hologic (HOLX): Leadership, Earnings Preview, Market Analysis
Analysis of Hologic (HOLX): New board member, Q2 earnings preview, economic headwinds, and surgical growth. Key insights for investors.
Hologic (HOLX) Rejects $16B Bid, Focuses on Innovation & Growth
Hologic's board rejected a $16B take-private offer, signaling confidence in its strategic direction and innovation in women's health diagnostics.
Hologic Inc. (HOLX): Strategic Independence & Diagnostics Growth
Hologic Inc. (HOLX) recently rejected a $16 billion buyout, signaling strong confidence in its strategic independence and high-margin diagnostics growth.
Hologic's Financial Rebound: Strategic Growth in Women's Health
Hologic's FY2024 net income surged +73.14% to $789.5MM, signaling a robust recovery and strategic pivots in women's health diagnostics and breast health.
Hologic, Inc. Strategic Capital Deployment and Diagnostic Innovation Driving Growth
Explore how Hologic's disciplined capital deployment, innovative diagnostics, and strategic acquisitions underpin its resilient growth and market leadership.
Hologic Inc. Financial Analysis: Strategic Growth Amidst Sector Challenges | Monexa AI
Explore Hologic's latest financials, strategic acquisitions, and market dynamics shaping its position in medical diagnostics and surgical solutions.
Hologic, Inc. Financial Analysis and Market Update: AI Innovations and Strategic Growth Drivers
Explore Hologic's latest financial performance, AI breast health innovations, market challenges, and strategic growth drivers shaping investor outlook.
Hologic Inc Q3 Earnings Analysis: Segment Growth and Strategic Resilience Amid Headwinds
Hologic's Q3 earnings highlight segment growth in Skeletal Health and GYN Surgical amid tariffs and geopolitical challenges, supported by AI innovation and robust cash flow.
Hologic Inc Q3 2025 Earnings Beat Amid Margin Pressures and Regional Headwinds | Monexa AI Analysis
Hologic Inc beats Q3 earnings estimates with revenue growth but faces margin contraction from tariffs, product mix shifts, and regional challenges in China and Africa.
Hologic, Inc. (HOLX) Latest Corporate Developments and Financial Insights
Comprehensive analysis of Hologic's recent financial performance, strategic moves, and market positioning with data-driven insights for investors.
Hologic Q3 2025 Earnings Beat Highlights Diagnostics Growth and AI Innovation | Monexa AI
Hologic's Q3 2025 results showcase strong diagnostics growth and AI-driven breast health advances, overcoming geopolitical headwinds with robust financials.
Hologic, Inc. (HOLX): Profit Spike, Flat Revenue — Is Execution the Make‑or‑Break Story?
Hologic reported **FY2024 revenue of $4.03B (0.00% YoY)** and **net income of $789.5M (+73.14% YoY)**; the gap between flat top line and rising profits frames 2026 as an execution test.
Hologic (HOLX): Diagnostics Growth vs. Breast Health Rebound — Financial Readiness and Execution Risk
Hologic reported **Q3 2025 revenue $1.02B** and guidance of **$4.081–$4.091B**; Diagnostics holds the growth engine while Breast Health must execute a 2026 hardware/software rebound.
Hologic Accelerates Strategic Expansion Through Acquisitions and Diagnostic Innovation
Women's health specialist advances interventional capabilities with Endomagnetics deal while expanding Panther Fusion menu and forging diagnostic partnerships.